A Critical Review of Multimodal Interventions for Cachexia
- PMID: 32970097
- PMCID: PMC8262513
- DOI: 10.1093/advances/nmaa111
A Critical Review of Multimodal Interventions for Cachexia
Abstract
Currently, there are no standardized treatments for cachexia or severe wasting. There is a growing consensus advocating multimodal interventions to address the complex pathogenesis and metabolic alterations in these conditions. This review examined multimodal treatments intended to alleviate and/or stabilize cachexia and severe wasting. The objectives of this review were to 1) identify multimodal interventions for the treatment of cachexia or associated wasting syndromes in patients with a chronic illness, 2) assess the quality of these studies, and 3) assess the effectiveness of multimodal interventions. Electronic databases including PubMed, MEDLINE, EMBASE, Scopus, Web of Science, Cochrane Library, CINAHL, PEDro, OpenGrey, and clinicaltrials.org were systematically searched using both text words and MeSH (medical subject heading) terms. The literature revealed a dearth of large, well-conducted trials in this area. Fourteen trials (n = 5 cancer, n = 5 chronic obstructive pulmonary disease, n = 4 chronic kidney disease) were included in this review. A total of 1026 patients were included across all studies; sample size ranged between 21 and 138 patients. Baseline and follow-up data were collected between 6 wk and 24 mo. All demonstrated some improvement in favor of the treatment groups, in relevant measures of body composition, nutrition, biomarkers, and functionality; however, caution should be applied due to the heterogenous nature of the interventions and small sample sizes. Overall, the evidence from this review supports the role of multimodal interventions in the treatment of severe wasting. However, randomized controlled trials with a powered sample size and sufficiently lengthy interaction period are necessary to assess if multimodal interventions are effective forms of therapy for improving body composition and nutritional and physical status in patients with cachexia and wasting. The protocol for this review is registered with Prospero (ID: CRD42019124374).
Keywords: cachexia; interventions; multimodal; review; wasting.
© The Author(s) 2020. Published by Oxford University Press on behalf of the American Society for Nutrition.
Similar articles
-
Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881. Med J Aust. 2020. PMID: 33314144
-
Can Exercise Counteract Cancer Cachexia? A Systematic Literature Review and Meta-Analysis.Integr Cancer Ther. 2020 Jan-Dec;19:1534735420940414. doi: 10.1177/1534735420940414. Integr Cancer Ther. 2020. PMID: 32954861 Free PMC article.
-
Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series.J Cachexia Sarcopenia Muscle. 2023 Oct;14(5):1932-1948. doi: 10.1002/jcsm.13321. Epub 2023 Sep 6. J Cachexia Sarcopenia Muscle. 2023. PMID: 37671529 Free PMC article.
-
Evidence base for multimodal therapy in cachexia.Curr Opin Support Palliat Care. 2012 Dec;6(4):424-31. doi: 10.1097/SPC.0b013e328359b668. Curr Opin Support Palliat Care. 2012. PMID: 23111703 Review.
-
Contraction and nutrition interaction promotes anabolism in cachectic muscle.Curr Opin Clin Nutr Metab Care. 2019 Jan;22(1):60-67. doi: 10.1097/MCO.0000000000000527. Curr Opin Clin Nutr Metab Care. 2019. PMID: 30461449 Review.
Cited by
-
Multicomponent Interventions for Adults With Cancer Cachexia: A Systematic Review.J Cachexia Sarcopenia Muscle. 2025 Apr;16(2):e13716. doi: 10.1002/jcsm.13716. J Cachexia Sarcopenia Muscle. 2025. PMID: 40012451 Free PMC article.
-
Targeting cancer cachexia: Molecular mechanisms and clinical study.MedComm (2020). 2022 Sep 10;3(4):e164. doi: 10.1002/mco2.164. eCollection 2022 Dec. MedComm (2020). 2022. PMID: 36105371 Free PMC article. Review.
-
Leucine Supplementation in Cancer Cachexia: Mechanisms and a Review of the Pre-Clinical Literature.Nutrients. 2022 Jul 9;14(14):2824. doi: 10.3390/nu14142824. Nutrients. 2022. PMID: 35889781 Free PMC article. Review.
-
The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers.J Cachexia Sarcopenia Muscle. 2021 Feb;12(1):14-16. doi: 10.1002/jcsm.12675. Epub 2020 Dec 31. J Cachexia Sarcopenia Muscle. 2021. PMID: 33382205 Free PMC article.
-
Validity of the diagnostic criteria from the Asian Working Group for Cachexia in advanced cancer.J Cachexia Sarcopenia Muscle. 2024 Feb;15(1):370-379. doi: 10.1002/jcsm.13408. Epub 2023 Dec 19. J Cachexia Sarcopenia Muscle. 2024. PMID: 38115133 Free PMC article.
References
-
- Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani Get al. . Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95. - PubMed
-
- Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006;83(4):735–43. - PubMed
-
- Crawford J. What are the criteria for response to cachexia treatment?. Ann Palliat Med. 2019;8(1):43–9. - PubMed
-
- Di Girolamo FG, Guadagni M, Fiotti N, Situlin R, Biolo G. Contraction and nutrition interaction promotes anabolism in cachectic muscle. Curr Opin Clin Nutr Metab Care. 2019;22(1):60–7. - PubMed
-
- Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani Get al. . Cachexia: a new definition. Clin Nutr. 2008;27(6):793–9. - PubMed